Women’s Health Advances: A New NIH Division And Menopause-Stage Obesity Data
Trial status and details compiled from ClinicalTrials.gov. Results and topline data drawn from sponsor releases or publications, where applicable. Regulatory information drawn from the FDA. Research accurate as of 24/10/2026.
Over the last couple of weeks, there have been several developments in women’s health and metabolic medicine, spanning research, policy, and regulatory landscapes. An executive order directed the Department of Health and Human Services to establish a new Women’s Health Division, and a post-hoc analysis of the Phase 3 REDEFINE 1 trial was presented at The Menopause Society’s 2026 Annual Meeting, looking at how an investigational weight-loss treatment performed across menopausal stages. Survey data presented at the same meeting looked at the challenges faced by women because of difficulties obtaining their estrogen patch prescriptions due to disrupted access. In other news, new exploratory data looks at a potential immune and metabolic connection between psoriasis and obesity, and the FDA has granted accelerated approval for an immunotherapy that may allow some patients with rectal cancer to avoid surgery.
White House Directs HHS to Create a Women’s Health Division
While there are notable advances in healthcare and biomedical science, there have historically been gaps in the research and clinical attention given to conditions that are either unique to women or disproportionately affect them. This is alongside the underrepresentation of women in clinical trials.
To address this longstanding gap, the President signed an executive order on the 19th of October 2026 called Advancing Women’s Health to Improve Outcomes in All Phases of Life, which directs the U.S. Department of Health and Human Services (HHS) to establish a Women’s Health Division within a National Institutes of Health (NIH) center or institute over a 90-day timeframe. This new division will coordinate with the existing NIH Office of Research on Women’s Health to identify research priorities, including understudied women’s health conditions across different phases of life, improve access to preventive care and interdisciplinary treatment for health conditions affecting women over the course of their lives (such as menopause, PMOS, cancer, cardiovascular disease, and endometriosis, among others), and support the inclusion of women and girls in clinical trials.
The Executive Order also establishes a White House Women’s Health Task Force, which aims to coordinate women’s health initiatives across the federal government and ensure that the findings of the Women’s Health Division are actioned and implemented into clinical practice and public health policy.
The Society for Women’s Health Research (SWHR), the American College of Obstetricians & Gynecologists (ACOG), and the Women First Research Coalition (WFRC) released a joint statement in response to the Executive Order, welcoming the establishment of the new women’s health division and the White House Women’s Health Task Force, which would make women’s health and research a greater priority across the federal government. It also aligns with their National Strategy to Close the Women’s Health Gap, which was launched earlier this year, seeking to secure a $20 billion, 10-year commitment from Congress to rectify the gaps in women’s healthcare. The impact of the Executive Order will depend on its implementation and funding.
CagriSema’s Weight-Loss Results Analyzed by Menopause Stage
Novo Nordisk reported results on the 20th October 2026 of two post hoc analyses (statistical analyses performed after completion of the study) of its Phase 3 REDEFINE 1 trial, which were presented at The Menopause Society’s 2026 Annual Meeting this month. The REDEFINE 1 trial evaluated CagriSema, an investigational combination of a long-acting amylin analogue (cagrilintide) with a GLP-1 medicine (semaglutide), in 3400 adults with overweight or obesity.
The first post hoc analysis looked specifically at the 2309 women who were part of the trial, and found that at week 68, CagriSema (2.4 mg/2.4 mg) was associated with an average weight loss of 25% in comparison to 3% with placebo. This estimated efficacy was based on all patients staying on treatment and not using any other weight-loss therapies.
The second post hoc analysis grouped 1902 of the women in the trial according to their menopausal status, which was based on their age, medical history, and symptoms. At week 68, CagriSema (2.4 mg/2.4 mg) was associated with an average weight loss of 26.7% in premenopausal women (2.1% with placebo), 24.8% in perimenopausal women (1.7% with placebo), and 23.1% in postmenopausal women (2.6% with placebo). These results show substantial weight loss across the menopause subgroups, but again this is based on an efficacy estimand assuming all patients stayed on treatment and did not take other weight-loss therapies.
Novo Nordisk described these post hoc analyses as ‘hypothesis generating’, with the results needing further investigation for clinical validation. Although these two analyses are exploratory, they are interesting as the menopausal transition is a factor not usually specifically examined in obesity research, and they provide some (very early) insight as to weight-loss outcomes stratified by menopause status.
Novo Nordisk submitted a New Drug Application with the FDA last year, December 2025, for CagriSema, and a decision is expected in the last quarter of 2026.
Trial record: NCT05567796
Midi Health Survey Highlights Challenges Accessing Estradiol Patches
Midi Health (a telehealth provider for women) presented a survey titled Rapid Survey of Women’s Experiences Getting Estrogen Patches in 2026 at The Menopause Society’s 2026 Annual Meeting this month on 22nd October. The study looked at the challenges faced by women in early 2026 with their estrogen patch prescriptions because of disrupted access, as well as the subsequent impact on symptoms and decisions regarding continuity of care.
The survey was emailed to 71385 Midi Health newsletter subscribers, and 7281 responses were received. 7067 respondents reported that they used estrogen patches, with 44% encountering difficulties having their prescriptions filled in 2026. Of those respondents experiencing difficulties, 34% said that their pharmacy was out of stock. In response to this challenge, 55% of the women switched pharmacies, 28% rationed their existing doses of medication, and 10% stopped their hormone therapy completely. 39% of respondents reported a return or worsening of their (peri)menopausal symptoms. The study abstract will be published in Menopause, which is The Menopause Society’s journal.
Although these findings highlight the effect that supply disruptions can have on patients, the survey results should be read alongside their limitations. The survey went out to subscribers of one telehealth provider’s newsletter, which may not be a representative sample of all women using menopausal hormone therapy.
While the FDA has not declared a shortage of estradiol transdermal patches, the agency has acknowledged that it is aware of some patients experiencing difficulties accessing their usual patches because of an increase in demand and is working with manufacturers to increase supply. On the other hand, the American Society of Health-System Pharmacists added estradiol transdermal systems to its shortage database in January 2026 and is currently listing 17 formulations on the shortage list, which was last updated in August.
The Link Between Psoriasis and Obesity
On October 9th 2026, Eli Lilly reported new exploratory data on immune and metabolic biomarker findings from the Phase 3b TOGETHER-PsO trial, which was presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas. The trial enrolled 281 adult participants with moderate-to-severe plaque psoriasis (an autoimmune skin condition resulting in dry, scaly, itchy patches) and obesity or overweight with at least one additional weight-related comorbidity and evaluated the use of Taltz (ixekizumab) and Zepbound (tirzepatide) combined in comparison to Taltz alone. Taltz is a biologic prescription medication and is a type of protein that is designed to target specific parts of the immune system. It is used to treat conditions including plaque psoriasis. Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist and is an obesity medication.
This was an assessor-blinded open-label trial, which means that both participants and treating clinicians know which treatment is being given, but the people evaluating the results do not know. Eli Lilly reported topline results from the trial earlier this year (February 2026) that the combination delivered improved skin clearance and weight loss compared to Taltz on its own after 36 weeks.
The new analysis aimed to better understand the immune and metabolic connection between psoriasis and obesity by observing changes in biomarkers. The analysis found that at week 36, the combination of Taltz and Zepbound was associated with a greater number of changes in psoriasis-specific, immune, and metabolic biomarkers compared to treatment with Taltz alone. While these exploratory findings are interesting, and the changes in biomarkers may suggest a potential immune and metabolic connection between psoriasis and obesity, the biomarker findings do not necessarily translate into improved clinical outcomes.
Trial record: NCT06588283
FDA Approves Immunotherapy For Certain Locally Advanced Rectal Cancers
Locally advanced rectal cancer is typically treated with chemotherapy and radiation before surgical intervention, with these treatments often having negative effects on the bowel and bladder with implications for fertility and sexual function.
Dostarlimab (Jemperli) is an immunotherapy medication that was granted accelerated approval by the FDA on the 19th of October 2026 for the treatment of adults with a certain type of previously untreated Stage II or III locally advanced rectal cancer. This may be either microsatellite instability-high or mismatch repair-deficient types. The FDA approval was based primarily on interim results from an open-label phase 2 trial called AZUR-1, which involved 154 participants with this specific type of locally advanced rectal cancer and investigated the efficacy of Jemperli monotherapy. According to the FDA, after a median follow-up of over 2 years (which means that at least half of the participants were monitored for that duration), 110 patients (71%) received Jemperli alone and had no additional treatment, as well as no disease progression.
Immunotherapy with Jemperli could allow certain patients to avoid chemotherapy, radiotherapy, or surgery. However, the FDA approval is accelerated, and further evidence is needed regarding any clinical benefits and safety.
Trial record: NCT05723562
Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. Consult a qualified healthcare professional regarding specific health questions.